| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 4 | +25.00% | +4.40% | +0.14% | +4.25% | +4.79% | — |
| 14d | 4 | +50.00% | +2.06% | -1.21% | +3.27% | +6.12% | — |
| 30d | 4 | +100.00% | -7.92% | +0.02% | -7.94% | -4.32% | — |
| 60d | 4 | +50.00% | +77.77% | -1.60% | +79.37% | +82.39% | — |
| 90d | 4 | +50.00% | +106.69% | -3.75% | +110.44% | +113.40% | — |
| 180d | 4(1 pending) | +33.33% | +204.86% | +6.59% | +198.27% | +304.79% | — |
| 1y | 4(3 pending) | +100.00% | -21.83% | +15.76% | -37.59% | -37.59% | — |
| 2y | 4(4 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Strategy Officer | 2,858 | $1.01 | $2.9K | 59,086 | Jan 6, 2026 | Jan 7, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Strategy Officer | 3,604 | $1.00 | $3.6K | 61,944 | Jan 5, 2026 | Jan 7, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Strategy Officer | 765 | $1.14 | $872 | 65,548 | Nov 4, 2025 | Nov 6, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 28,000 | — | — | 61,313 | Feb 26, 2025 | Feb 28, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 56,000 | — | — | 56,000 | Feb 26, 2025 | Feb 28, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Strategy Officer | 2,029 | $1.34 | $2.7K | 33,313 | Jan 3, 2025 | Jan 7, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 20,250 | — | — | 20,250 | Nov 4, 2024 | Nov 5, 2024 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 10,125 | — | — | 35,342 | Nov 4, 2024 | Nov 5, 2024 ↗ | View → |